A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Pfizer
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Wake Forest University Health Sciences
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
University of Chicago
City of Hope Medical Center
Mayo Clinic
National Cancer Institute (NCI)
University of Miami
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)